Gout Treatment Denied by Insurance? How to Appeal

Gout is the most common inflammatory arthritis in the United States, affecting more than 9 million Americans. When managed properly, gout is largely controllable. Yet insurance companies frequently deny coverage for pegloticase (Krystexxa), febuxostat (Uloric), colchicine (Colcrys), and even allopurinol — leaving patients in excruciating pain with progressive joint and organ damage. This guide explains common gout treatment denials and how to appeal effectively.

Why Insurers Deny Gout Treatment

Pegloticase (Krystexxa) denied — Krystexxa is FDA-approved for treatment-refractory chronic gout and is the most powerful urate-lowering therapy available. Insurers impose strict Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization criteria: documented failure of allopurinol at maximum tolerated dose, failure of febuxostat, and persistent serum uric acid (sUA) above 6 mg/dL. Some plans also require documentation of tophi or chronic gouty arthropathy. At $20,000+ per infusion cycle, Krystexxa faces aggressive denial.

Febuxostat (Uloric) denied — Insurers often require failure of allopurinol before approving febuxostat. The 2019 FDA boxed warning about cardiovascular events with febuxostat (based on the CARES trial) has given some insurers additional grounds to restrict it — though the ACR guideline notes febuxostat remains appropriate for patients with allopurinol intolerance or suboptimal allopurinol response.

Colchicine denied — Brand-name Colcrys is expensive; generic colchicine is widely available but some plans deny the branded product without step therapy. However, dosing of colchicine for acute gout flare prophylaxis is well-established and denial of colchicine (any formulation) for an active flare is clinically indefensible.

Allopurinol dose denied — Some plans cap allopurinol coverage at lower doses (e.g., 300 mg/day) when patients need up to 800 mg/day to reach sUA target. Denials for higher doses are appealed by documenting the treat-to-target approach and the failure to achieve sUA <6 mg/dL at lower doses.

Step therapy not completed — All advanced gout therapies face step therapy requirements mandating documented failure of at least one conventional ULT (typically allopurinol at maximum tolerated dose) before approving alternatives.

Clinical Frameworks Supporting Your Appeal

ACR Gout Guideline (2020) — The American College of Rheumatology's 2020 Guideline for the Management of Gout recommends a treat-to-target strategy: titrating urate-lowering therapy (ULT) to achieve sUA <6 mg/dL in most patients, and <5 mg/dL in patients with tophi. Allopurinol is the first-line ULT and should be dose-escalated to achieve sUA target. If allopurinol alone does not achieve target at maximum tolerated dose, febuxostat or combination therapy is appropriate. If all oral ULTs fail, pegloticase is appropriate for refractory gout.

Serum Uric Acid Target — Document your sUA levels over time with dates. An sUA above 6 mg/dL on maximum-tolerated allopurinol constitutes failure of first-line therapy. Persistent hyperuricemia above this threshold drives crystal deposition, tophi formation, and joint destruction. Present the trend data in your appeal.

Allopurinol Intolerance and Allergy — Allopurinol causes hypersensitivity reactions in approximately 2% of patients, ranging from rash to Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-B*58:01 genotype (common in Asian populations) markedly increases SJS risk. If you cannot take allopurinol due to documented hypersensitivity, document this carefully — it is a Class I indication for step therapy override and direct approval of febuxostat or pegloticase.

Renal Insufficiency Context — Allopurinol dosing in chronic kidney disease (CKD) is complex. Patients with CKD may not tolerate therapeutic doses of allopurinol. ACR guidelines acknowledge reduced allopurinol tolerability in CKD and support febuxostat as a reasonable alternative in this population.

Pegloticase MIRROR Trial — For Krystexxa prior authorization, the MIRROR trial demonstrated significantly improved response rates when pegloticase was combined with immunomodulation (methotrexate or mycophenolate). If your prescriber is requesting combination pegloticase + immunomodulator, cite MIRROR trial data.

Step-by-Step Appeal Strategy

Step 1: Document your sUA trend. Print a table of your serum uric acid values over the past 12–24 months, showing persistent elevation above 6 mg/dL despite treatment. This is the most important piece of documentation for any advanced ULT appeal.

Step 2: Document the allopurinol trial. Record maximum dose tried, duration, laboratory results at each dose, reason for dose limitation (renal function, side effects, gastrointestinal intolerance), and any hypersensitivity reactions.

Step 3: Document gout burden objectively. Include: number of acute flares in the past 12 months, duration of each flare, any tophi (with imaging if available), joint involvement, impact on ambulation and work, and any radiographic damage (joint erosions, punched-out lesions).

Step 4: Submit the ACR treat-to-target documentation. Your rheumatologist should document the treat-to-target strategy and explain why the requested medication is necessary to reach the sUA target that the current regimen has failed to achieve.

Step 5: File an internal appeal with a specialist Letter of Medical Necessity. Include sUA trend data, flare count, allopurinol trial documentation, and any evidence of tophi or joint damage. For Krystexxa, also include the documentation of failed alternative ULTs.

Step 6: Request external independent review if denied. External reviewers apply ACR guideline standards. Gout appeals with complete documentation of refractory disease and failed conventional therapy succeed frequently at external review.

The Undertreatment Problem

Most gout patients are undertreated because of a combination of poor prescribing, medication adherence challenges, and insurance barriers. The ACR estimates that less than 40% of patients with gout receive appropriate ULT. Insurance denials contribute to this treatment gap and its downstream consequences: tophi, gouty arthropathy, nephrolithiasis, and CKD progression from chronic hyperuricemia.

Fight Back With ClaimBack

You should not be living in pain because your insurer refuses to cover effective gout treatment. ClaimBack helps you document your uric acid history, allopurinol trial, flare count, and the ACR guidelines that support your appeal.

Start your gout treatment appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals